Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Ascendis Pharma, with a price target of $254.00. Thom...

Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. Archila cove...

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

By the end of this month, two pharmaceutical firms are set to receive a decision on their drug approval applications from the U.S. Food and Drug Ad...

FDA Calendar: These Are the Upcoming FDA Drug Approvals 

In a report released on November 14, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. The...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Alkerme...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Alkermes (ALKS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $250.00. According ...

Market Cap	$11.93B	P/E Ratio	N/A
52W High	$229.94	52W Low	$118.03
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	91.5%
Overall Score	75	Value Score	--
Quality Score	60	Technical Score	90

EPS Current Est	$-3.41	EPS Next Est	$3.21
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$220.42	+4.88%	1.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$220.42	+4.9%	1.43M
3
4
5
6

ASND

ASND

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel